ArticleThe American journal of the medical sciences2007
Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.
Article in The American journal of the medical sciences, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.AIDS (London, England) · 2009Trial
- Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States.Infectious diseases and therapy · 2025Article
- HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases.Frontiers in medicine · 2021Review
- Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?Clinical and molecular hepatology · 2017Article
- Assessment of the effect of antiretroviral therapy on renal and liver functions among HIV-infected patients: a retrospective study.HIV/AIDS (Auckland, N.Z.) · 2017Article
- Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers.The Indian journal of medical research · 2016Review
- Antiretroviral therapy: current drugs.Infectious disease clinics of North America · 2014Review
- Characteristics of Hepatitis B Co-infection and Disease Evolution in HIV-Positive Paediatric Patients in Romania.Balkan medical journal · 2013Article
- Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses.The Journal of infectious diseases · 2013Article
- Elevated alanine aminotransferase in antiretroviral-naïve HIV-infected African patients: magnitude and risk factors.HIV medicine · 2012Article
- Opportunities in proteomics to understand hepatitis C and HIV coinfection.Future virology · 2012Article
- A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2012Article
- HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.Current HIV/AIDS reports · 2011Review
- Development of fatal acute liver failure in HIV-HBV coinfected patients.World journal of gastroenterology · 2010Article
- Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda.International journal of STD & AIDS · 2010Article
- Immune restoration diseases reflect diverse immunopathological mechanisms.Clinical microbiology reviews · 2009Review
- Adverse drug reaction monitoring in patients on antiretroviral therapy in a tertiary care hospital in Eastern India.Indian journal of pharmacologyObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesBecause liver enzymes elevation (LEE) complicates antiretroviral (ARV) therapy, and because the strongest risk factor for ARV-related LEE is HBV/HCV coinfection, it is speculated that ARV-related LEE may be a form of immune reconstitution disease. This study summarizes the relation between immune reconstitution, ARV-induced LEE, and HBV/HCV coinfection.
methodsMedical records of ARV-naïve HIV-infected patients initiating ARV were reviewed for hepatitis coinfection, LEE (grade > or =2 AST/ALT) and changes in CD4 T-cell counts over time in an urban HIV clinic. Risk factors for LEE were statistically evaluated, and changes in CD4 T-cell counts were estimated by a mixed-effects linear model.
resultsPredictors of LEE included HBV/HCV coinfection (OR = 6.44) and stavudine use (OR = 2.33). Nelfinavir use was protective (OR = 0.45). The mean rate of change in CD4 T-cell counts was higher in HBV/HCV coinfected subjects who developed LEE (99 cells/microL per month) compared with non-coinfected subjects who did not develop LEE (59 cells/microL per month, P = 0.03), non-coinfected subjects who developed LEE (36 cells/microL per month, P =0.01), and coinfected subjects who did not develop LEE, 38% higher (62 cells/microL per month; P =0.11)
conclusionsA more robust immune restoration was observed among HBV/HCV coinfected subjects who developed liver enzyme elevation after antiretroviral initiation compared with other groups. This finding suggests that ARV-related liver enzyme elevation may be related in part to immune reconstitution, as measured by changes in CD4 T-cell counts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.